Emcure Pharmaceuticals Limited (NSEI: EMCURE)
Health Care · Pharmaceuticals · IN
Rs1,932.30
-2.33% today · +32.9% 1Y
Emcure Pharmaceuticals Limited (NSEI: EMCURE) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.83B and employs 6,731 people.
Over the last twelve months the share price has gained 32.9%, trading between 1.26K and 2.01K.
Tweenvest scores Emcure Pharmaceuticals Limited across four factors: quality 67/100, value 28/100, growth 68/100, dividend 40/100. Its strongest factor is growth.
EMCURE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.83B
- Revenue (TTM)
- $1.02B
- P/E
- 36.22
- EPS
- 53.35
- Dividend yield
- 0.19%
- Beta (5Y)
- -0.06
- 52-week high
- Rs2,009.20
- 52-week low
- Rs1,260.00
- Avg volume (3M)
- —
- Shares outstanding
- 189.59M
- Employees
- 6,731
- Next earnings
- —
About Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited is committed to providing high-quality, cost-effective healthcare solutions to a global market. The company boasts a diverse product lineup spanning numerous medical fields, such as women's health (gynecology), anti-infectives, pain relief, nutritional supplements (vitamins, minerals, and nutrients), hematology, oncology, respiratory treatments, HIV antivirals, gastrointestinal remedies, anti-diabetics, neurological medications, and cardiovascular therapies. Notable brand names under their umbrella include Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym. Founded in 1981, Emcure Pharmaceuticals Limited is headquartered in Pune, India.
- ISIN
- INE168P01015
- Founded
- 1981
- Listed since
- Jul 10, 2024
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.